Last reviewed · How we verify
EMS Acarbose
Acarbose inhibits intestinal alpha-glucosidase enzymes to slow carbohydrate digestion and reduce postprandial glucose spikes.
Acarbose inhibits intestinal alpha-glucosidase enzymes to slow carbohydrate digestion and reduce postprandial glucose spikes. Used for Type 2 diabetes mellitus.
At a glance
| Generic name | EMS Acarbose |
|---|---|
| Sponsor | EMS |
| Drug class | Alpha-glucosidase inhibitor |
| Target | Alpha-glucosidase enzymes (intestinal brush border) |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Acarbose is an alpha-glucosidase inhibitor that delays the breakdown and absorption of disaccharides and polysaccharides in the small intestine. By slowing glucose absorption, it reduces postprandial blood glucose peaks in patients with type 2 diabetes. This mechanism helps improve glycemic control without stimulating insulin secretion.
Approved indications
- Type 2 diabetes mellitus
Common side effects
- Gastrointestinal disturbances (flatulence, diarrhea, abdominal discomfort)
- Abdominal pain
- Diarrhea
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |